On Monday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was 3.41% up from the session before settling in for the closing price of $0.80. A 52-week range for ADAP has been $0.42 – $2.05.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 134.88% over the past five years. When this article was written, the company’s average yearly earnings per share was at 58.61%. With a float of $226.31 million, this company’s outstanding shares have now reached $227.17 million.
Let’s look at the performance matrix of the company that is accounted for 449 employees. In terms of profitability, gross margin is 92.0%, operating margin of -58.73%, and the pretax margin is -54.99%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adaptimmune Therapeutics Plc ADR stocks. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 49.25%. The most recent insider transaction that took place on Jun 18 ’24, was worth 22,814. In this transaction Chief Commercial Officer of this company sold 24,531 shares at a rate of $0.93, taking the stock ownership to the 38,293 shares. Before that another transaction happened on Jan 17 ’24, when Company’s Chief Executive Officer sold 30,080 for $0.67, making the entire transaction worth $20,244. This insider now owns 44,848 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 58.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.00% during the next five years compared to 10.30% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
You can see what Adaptimmune Therapeutics Plc ADR (ADAP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) saw its 5-day average volume 0.65 million, a negative change from its year-to-date volume of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 68.02%. Additionally, its Average True Range was 0.06.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 19.00%, which indicates a significant decrease from 81.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.10% in the past 14 days, which was lower than the 77.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9152, while its 200-day Moving Average is $1.1306. Nevertheless, the first resistance level for the watch stands at $0.8463 in the near term. At $0.8686, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9037. If the price goes on to break the first support level at $0.7889, it is likely to go to the next support level at $0.7538. The third support level lies at $0.7315 if the price breaches the second support level.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are 255,745K outstanding shares of the company, which has a market capitalization of 210.72 million. As of now, sales total 60,280 K while income totals -113,870 K. Its latest quarter income was 128,230 K while its last quarter net income were 69,520 K.
